• In the first quarter of 2026, Madrigal Pharmaceuticals reported a net loss of US$94.39 million as Rezdiffra generated US$311.3 million in revenue and the company broadened its MASH pipeline, including licensing Arrowhead’s clinical-stage siRNA asset ARO‑PNPLA3.
• By pairing blockbuster-level Rezdiffra sales with an expanded portfolio of genetic and metabolic MASH candidates, Madrigal is shifting from a single‑drug story toward a broader, combination-focused franchise in liver disease.
• We’ll now examine how Rezdiffra’s blockbuster-level revenue growth and the ARO‑PNPLA3 license reshape Madrigal’s investment narrative for investors.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Madrigal Pharmaceuticals Investment Narrative Recap

To own Madrigal today, you need to believe Rezdiffra can remain the anchor of a multi‑asset MASH franchise while the company absorbs sizable losses to build out combinations and new modalities. The latest quarter, with a US$94.39 million net loss alongside US$311.3 million in Rezdiffra revenue and the ARO‑PNPLA3 license, reinforces that the near term swings on continued Rezdiffra uptake and the MAESTRO outcomes program, while cash burn and spending discipline remain key risks.

The licensing of Arrowhead’s ARO‑PNPLA3 looks most relevant here because it ties directly into Madrigal’s goal of making Rezdiffra a “backbone” therapy that can be paired with genetic and metabolic add‑ons. Earlier deals like the Pfizer ervogastat agreement and the planned MGL‑2086 oral GLP‑1 trial sit in the same bucket of combination catalysts, but ARO‑PNPLA3 is the first clinically de‑risked, mutation‑targeted asset that could eventually clarify just how broad Madrigal’s MASH toolkit might become.

Yet beneath the blockbuster‑level Rezdiffra revenue, investors should be aware of the growing tension between rapid pipeline build‑out and...

Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $671.07 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already penciling in about US$3.6 billion of revenue and US$1.5 billion of earnings by 2028, so if you buy that view you are accepting much higher expectations than the baseline and this quarter’s ARO‑PNPLA3 deal and US$311.3 million in Rezdiffra sales could either support or challenge those assumptions as the story evolves.

Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 14% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.